Replacing a phosphodiesterase-5 inhibitor with riociguat in patients with connective tissue disease-associated pulmonary arterial hypertension: a case series

Amresh Raina¹, Raymond L. Benza¹ and Harrison W. Farber²
¹Cardiovascular Institute, Allegheny General Hospital, Allegheny Health Network, Pittsburgh, PA, USA; ²Pulmonary Center, Boston University School of Medicine, Boston, MA, USA

Abstract
Patients with pulmonary arterial hypertension associated with connective tissue disease (PAH-PAH-CTD) such as systemic sclerosis (SSc) have a poorer response to treatment and increased mortality compared with patients with idiopathic PAH. Current treatment options for PAH-CTD include prostanoids, phosphodiesterase type-5 inhibitors (PDE-5i), endothelin receptor antagonists, and the soluble guanylate cyclase stimulator riociguat. In this case series, we describe three patients with PAH-CTD related to limited scleroderma who were switched from a PDE-5i to riociguat due to insufficient clinical response. The switch to riociguat was associated with an improvement in respiratory and hemodynamic parameters and a favorable tolerability profile. These cases demonstrate that switching to riociguat is a therapeutic option in patients with PAH-CTD who have not achieved a satisfactory clinical response to a PDE-5i.

Keywords
pulmonary arterial hypertension, connective tissue disease, systemic sclerosis, riociguat, soluble guanylate cyclase stimulators

Introduction
Pulmonary arterial hypertension (PAH) remains a progressive disease with high associated morbidity and mortality.¹ Fortunately, a variety of options are now available to treat PAH, including prostanoids, phosphodiesterase type 5 inhibitors (PDE-5i), soluble guanylate cyclase stimulators (sGCS), and endothelin receptor antagonists (ERA).² Because of cost and ease of use, PDE-5is are often utilized as first-line therapy, with additional medications added sequentially or as part of upfront combination therapy.³,⁴ Unfortunately, significant heterogeneity exists in terms of treatment response, such that alternative therapeutics with different modes of action are often required. Riociguat, the first-in-class sGCS, was approved in 2013 by the U.S. Food and Drug Administration for the treatment of adults with PAH (World Health Organization [WHO] Group 1) and in those with inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH; WHO Group 4).⁵,⁶ Riociguat targets the nitric oxide (NO) pathway to enhance cyclic guanosine monophosphate (cGMP) production; however, unlike PDE-5i, which inhibits degradation of cGMP, riociguat sensitizes sGC to endogenous NO by stabilizing NO–sGC binding and also directly stimulates sGC independent of NO via a different binding site.⁷,⁸ As NO synthesis and signaling are reduced in patients with PAH, and continue to decline as disease progresses, riociguat may be an attractive substitute for patients not responding clinically to PDE-5i therapy.⁹–¹¹ Use of riociguat with a PDE-5i is contraindicated.⁵,⁶

Heterogeneity to PAH-specific therapy and insufficient response to therapy can be particularly troublesome in...
PAH associated with connective tissue disease (PAH-CTD), especially if due to the scleroderma spectrum of diseases (PAH-SSc). Compared with idiopathic PAH (IPAH) patients, individuals with PAH-SSc have increased mortality and a poorer response to treatment.

In the subset of PAH-CTD patients naïve to PDE-5i therapy in the Pulmonary Arterial Hypertension Soluble Guanylate Cyclase-Stimulator Trial-1 (PATENT-1; n = 111, 66 with SSc), the least-squares mean treatment difference in six-minute walk distance (6MWD) at 12 weeks with riociguat (maximum 2.5 mg TID) was 28 m compared with 36 m in the overall study population. In patients with PAH-SSc receiving riociguat (n = 43), the mean increase in 6MWD at week 12 was 43 ± 20 m, but those patients receiving placebo (n = 16) showed a larger decrease of 37 ± 20 m.

In the PATENT-2 extension trial, at two years, mean 6MWD increased by 25 m from PATENT-1 baseline in patients with PAH-CTD (n = 70), while in the overall population, 6MWD increased by 47 m. Improvements in 6MWD were largely maintained in the PAH-SSc subpopulation as well.

Survival rates at one and two years were comparable for patients with PAH-CTD relative to the overall population: PAH-CTD = 97% (95% confidence interval [CI] = 90–99) at one year and 93% (95% CI = 85–97) at two years; overall population = 97% (95% CI = 95–98) at one year and 93% (95% CI = 90–95) at two years. The safety profile of riociguat in PAH-CTD patients was similar to that in the overall population.

Whether riociguat can be used as a substitute for a PDE-5i, or even preferentially, in patients with PAH-SSc is currently unknown; furthermore, the recently completed RESPITE clinical trial (NCT02007629) examining the effects of switching a PDE-5i to riociguat excluded patients with PAH-SSc as response to therapy is often mitigated in this subpopulation. In the current case series, we report the effect of switching to riociguat in three patients with PAH-SSc who had insufficient response to treatment with a PDE-5i.

**Case descriptions**

In each of the cases, SSc was diagnosed by American College of Rheumatology criteria and PAH diagnosed by standard approved criteria of mean pulmonary arterial pressure (mPAP) > 25 mmHg, pulmonary arterial wedge pressure (PAWP) ≤ 15 mmHg, and pulmonary vascular resistance (PVR) > 3 Wood units. Hemodynamic results from right heart catheterization (RHC) are shown in Tables 1 to 3.

**Case 1**

A 33-year-old woman presented with Raynaud’s phenomenon in 2003. In 2005, she developed ischemia of the second digit on her right hand and was diagnosed with limited scleroderma (antinuclear antibody [ANA] positive, 1:1280; centromeric pattern; centromere Ab positive; topoisomerase 1 [SCL-70] negative). Three years later, at age 38 years, she developed progressive dyspnea on exertion (DOE)/shortness of breath (SOB) affecting exercise tolerance and activities of daily living; imaging revealed minimal interstitial lung disease and she required supplemental O2 (WHO functional class [FC] III). The results of an echocardiogram and computed tomography pulmonary angiogram in January 2009 showed mild right ventricular (RV) enlargement with depressed systolic function, dilated inferior vena cava, pleural effusion, diffuse mosaic attenuation pattern.

**Table 1. Case 1: Key measurements from serial RHC.**

| Regimen | T | T + B + I | R + B + I | R + B + I |
|---------|---|----------|----------|----------|
| RHC Jan 2009 | Aug 2009 | April 2010 | Feb 2011 | Aug 2013 | Aug 2014 | Sep 2015 |
| mRAP (mmHg) | 11–12 | 10 | 5 | 4 | 13 | 10 | – |
| RVP (s/d/ed) (mmHg) | 53/0 | 55/–/4 | 42/3/7 | 63/25/5 | 67/9/10 | 70/6/8 | – |
| PAP (s/d) (mmHg) | 60/24 | 60/25 | 47/22 | 59/28 | 65/28 | 71/26 | – |
| mPAP (mmHg) | 39 | 37 | 32 | 41 | 44 | 45 | 43 |
| PCWP (mmHg) | 15 | 11 | 9 | 6 | 11 | 9 | – |
| PAox (L (%)) | – | 74 | 3 (75) | 2 (70) | – |
| CO (TD) (L/min) | 12.0 | 13.0 | 8.56 | 12.2 | 7.34 | 9.04 | 11.26 |
| CI (TD) (L/min/m²) | 4.6 | 4.9 | 3.24 | 4.92 | 2.89 | 3.57 | 4.31 |
| PVR (dyne·sec·cm⁻²) | 260 | 160 | 215 | 230 | 360 | 310 | 270 |

* Tadalafil was initiated in late 2009.  
* Bosentan was initiated after February 2011 RHC findings.  
* Imatinib was initiated after April 2013 diagnosis of CML.  
* Tadalafil was replaced with riociguat in November 2013 due to worsening hemodynamics.

B: bosentan; CI: cardiac index; CO: cardiac output; l: imatinib; mPAP: mean pulmonary artery pressure; mRAP: mean right atrial pressure; PAox: pulmonary arterial oxygen saturation; PAP: pulmonary arterial pressure; PCWP: pulmonary capillary wedge pressure; PVR: pulmonary vascular resistance; R: riociguat; RHC: right-heart catheterization; RVP: right ventricular pressure; s/d/ed: systolic/diastolic/end diastolic; T: tadalafil; TD, thermodilution.
interlobular septal thickening, and a pulmonary arterial systolic pressure (PAsp) of 58 mmHg; RHC revealed elevated right atrial pressure (RAP), right ventricular pressure, PAP, pulmonary capillary wedge pressure (PCWP), cardiac output (CO), and PVR (Table 1). PAH-CTD was diagnosed and the patient was treated aggressively with prednisone and mycophenolate mofetil due to SSc-associated skin tightening. An RHC in August 2009 showed improved cardiac output and PVR, but the patient remained WHO FC II–III with symptoms requiring supplemental oxygen at 2–3 L/min.

Tadalafil was initiated in late 2009 with stable-to-improved respiratory status (WHO FC II) and a RHC in April 2010 showed hemodynamic improvement with a cardiac index (CI) of 3.24 L/min/m² (decreased from 4.9 L/min/m²); a slight increase in PVR was seen (215 mmHg versus 160 mmHg) and had improved compared with baseline (PVR = 260 mmHg). A follow-up echocardiogram in December 2010 showed an increase in RV systolic pressure (RVSP) (59 mmHg versus 45 mmHg in January 2010) and a hypokinetic right ventricle; an RHC in February 2011 showed slight increases in PAP and PVR relative to April 2010 (Table 1). Due to worsening symptoms (WHO FC III) and digital ulcerations, bosentan was added in 2011. Her respiratory status initially improved (WHO FC II–III), but pulmonary function tests (PFTs) in April 2012 showed a severe decrease in carbon monoxide diffusion capacity (DLCO; 8.6 mL/min/mmHg). A repeat echocardiogram in January 2013 showed an increase in left ventricular ejection fraction (LVEF) and flow reversal into the hepatic veins; the patient was diagnosed with chronic myeloid leukemia (CML) in April 2013 and treated with imatinib with an excellent response (remission). A follow-up RHC in August 2013 showed increases in PAP and PVR despite therapy with two approved PAH drugs (bosentan and tadalafil) and imatinib, which has been investigated for treatment of PAH (despite significant improvements in hemodynamics, it was not approved to treat PAH due to adverse events). In November 2013, tadalafil was switched to riociguat (titrated to 2.5 mg TID without significant side effects) and the patient’s respiratory status improved (WHO FC II). Further evaluation in August 2014 showed decreased PVR with increased CO/CI; although the CO was elevated, the CI was actually low after accounting for

### Table 2. Case 2: Key measurements from serial RHC.

| Regimen | Sildenafil | Riociguat |
|---------|------------|-----------|
| RHC     |            |           |
| Mrap (mmHg) | Dec 2006 | Oct 2013 | May 2015 |
| RVP (s/d/ed) (mmHg) | 90/–1/NA | 88/2/4 | 94/4/11 |
| PAP (s/d) (mmHg) | 88/25 | 88/30 | 94/23 |
| Mmap (mmHg) | 48 | 54 | 53 |
| PCWP (mmHg) | 9–10 | 6 | 8 |
| PAst, L (%) | – | 60 | 58 |
| CO (TD) (L/min) | 4.3 | 3.07 | 4.67 |
| CI (TD) (L/min/m²) | 2.4 | 1.84 | 2.87 |
| PVR (dyn·s·cm⁻⁵) | 706 | 1199 | 771 |

*Sildenafil initiated in March 2007.

†Riociguat was replaced with riociguat in October 2013.

Cl, cardiac index; CO, cardiac output; mPAP, mean pulmonary artery pressure; mRAP, mean right atrial pressure; NA, not available; PAst, pulmonary arterial oxygen saturation; PAP, pulmonary arterial pressure; PCWP, pulmonary capillary wedge pressure; PFT, pulmonary function test; PVR, pulmonary vascular resistance; RHC, right-heart catheterization; RVP, right ventricular pressure; s/d/ed, systolic/diastolic/end diastolic; TD, thermodilution.

### Table 3. Case 3: Key measurements from serial RHC.

| Regimen | T | T + ITr | T + ITr + M | R + ITr + M |
|---------|---|--------|------------|------------|
| Mrap (mmHg) | Feb 2012, BL | Feb 2012, inhaled NO | Sept 2013 | Jan 2014 | Sep 2014 |
| RVP (s/d/ed) (mmHg) | 66/6/10 | NA | 69/2/4 | 85/–6/6 | 72/0/3 |
| PAP (s/d) (mmHg) | 66/35 | 60/30 | 68/22 | 82/24 | 71/18 |
| Mmap (mmHg) | 47 | 42 | 40 | 48 | 40 |
| PCWP (mmHg) | 11 | 10 | 11 | 5 | 3 |
| PAst, L (%) | 65 | – | 67 | 61 | 75 |
| CO (TD) (L/min) | 3.99 | 5.62 | 5.66 | 6.5 | 9.4 |
| CI (TD) (L/min/m²) | 2.07 | 2.91 | 3.11 | 3.51 | 5.23 |
| PVR (dyn·s·cm⁻⁵) | 597 | 456 | 375 | 646 | 393 |

*Inhaled treprostinil was added to tadalafil August 2012.

†Macitentan was added to tadalafil and inhaled treprostinil in October 2013.

‡Tadalafil was replaced with riociguat in February 2014. Inhaled treprostinil and macitentan were maintained.

Cl, cardiac index; CO, cardiac output; ITr, inhaled treprostinil; M, macitentan; MMAP, mean pulmonary artery pressure; MRAP, mean right atrial pressure; NA, not available; PAst, pulmonary arterial oxygen saturation; PAP, pulmonary arterial pressure; PCWP, pulmonary capillary wedge pressure; PFT, pulmonary function test; PVR, pulmonary vascular resistance; RHC, right-heart catheterization; R, riociguat; RVP, right ventricular pressure; s/d/ed, systolic/diastolic/end diastolic; TD, tadalafil; TD, thermodilution.
the patient’s body surface area. She remained stable to slightly improved at the most recent evaluation in September 2015.

Case 2
A 62-year-old woman was diagnosed with limited scleroderma (ANA+ 1:640; centromeric pattern; centromere Ab+; SCL-70 negative; rheumatoid factor [RF]+) in 2004. An echocardiogram performed in 2006 due to progressive DOE/SOB (WHO FC III) was suggestive of PAH, and RHC revealed elevated PAP, PVR, and systemic vascular resistance consistent with moderate PAH secondary to scleroderma (Table 2). She started sildenafil in March 2007 with marked improvement in respiratory status (WHO FC II). For the next five years, she remained very stable with no change in respiratory status clinically or on echocardiogram and was still working. In August 2013, a routine echocardiogram showed an increase in PAsp (78 mmHg versus 58 mmHg in August 2012). Because of these findings, she underwent surveillance RHC, which showed worsening hemodynamics compared with 2006, despite no change in symptoms (WHO FC II; still working) and a normal brain natriuretic peptide (BNP) of 71 pg/mL. Sildenafil was switched to riociguat (titrated to 2.5 mg TID without significant side effects) and her respiratory status was stable to slightly improved. Pulmonary function tests performed in May 2014 showed mild impairment with a forced expiratory volume in 1 s (FEV1) of 86%, forced vital capacity (FVC) of 78%, total lung capacity (TLC) of 69%, and DLco of 49%. In March 2015, an echocardiogram showed an increase in PAsp to 92 mmHg. Pulmonary function tests performed in May 2015 showed slight improvement in overall respiratory status (FVC = 91%; FEV1 = 97%) although DLco had decreased by 7% to 42%. Similarly, an RHC in May 2015 showed an overall improvement in hemodynamics although PVR was still elevated at 771 dyn·cm⁻⁵. In an attempt to further improve hemodynamic parameters, macitentan was added in July 2015. The patient initially experienced fluid retention with the addition of macitentan, which was managed with diuretics. She continues to take riociguat and macitentan.

Case 3
A 67-year-old woman was diagnosed with PAH-CTD due to limited SSc (ANA+ 1:80; centromeric pattern, centromere Ab+; SCL-70 negative; RF+) in February 2012. Over the previous year, she had been experiencing DOE/SOB and required 2 L/min continuous supplemental O2. She had advanced FC III–IV symptoms at presentation as confirmed by PFTs (FVC = 73%, FEV1/FVC = 70%, FEV1 = 80%, DLco = 37%) and RHC, and severe RV dysfunction (RV ejection fraction 29% on cardiac magnetic resonance imaging [MRI]) (Table 3). She also had concomitant, transient, LV dysfunction (LVEF 35%) which was felt to be secondary to RV-LV interaction in the context of massive RV dilatation (RV end diastolic volume 283 mL). Coronary angiography did not reveal any significant coronary disease and MRI showed no edema or contrast enhancement of the left ventricle other than at the RV insertion points. Given the advanced symptoms and an elevated Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL) score, she was initially treated with rapid titration of intravenous (IV) treprostinil, which resulted in elevated PCWP of 24 mmHg. IV treprostinil was discontinued, and she was subsequently started on tadalafil while the LV dysfunction was treated. Repeat echocardiogram in May 2012 revealed a normal LVEF of 65%. Inhaled treprostinil (9 breaths QID) was added to therapy six months later after LVEF had improved. Although she improved from February 2012 (WHO FC III, 6MWD = 235 m, N-terminal pro b-type natriuretic peptide [NT-proBNP] = 6112 pg/mL) to January 2013 (WHO FC II, 6MWD = 366 m, NT-proBNP = 823 pg/mL), her clinical status began to decline early in 2013 (FC III, 6MWD = 219 m with lowest O2 saturation 83%, NT-proBNP = 1361 pg/mL). RHC demonstrated persistent PAH (mPAP = 40 mmHg). Because of her previous inability to tolerate IV therapy, macitentan was added in October 2013. Although this led to some improvement (6MWD = 292 m without significant ambulatory desaturation), she remained WHO FC III with an increased NT-proBNP of 1501 pg/mL and an elevated REVEAL score of 12. RHC again demonstrated worsening PAP and PVR (Table 3). Because the patient was reluctant to add parenteral therapy, tadalafil was switched to riociguat (titrated to 2.5 mg TID) in February 2014. Following this change in therapy, WHO FC improved to FC II, 6MWD stabilized at 302 m, and, most notably, PVR decreased while CI increased. In terms of adverse effects, the patient experienced headache as well as reduction in blood pressure, requiring dose reduction in her antihypertensive agents. The patient remains on riociguat, macitentan, and inhaled treprostinil, which was increased to 12 breaths QID in mid-2015.

Discussion
Recently presented data from the RESPITE trial have shown that replacing PDE-5i therapy with riociguat may be of benefit in patients with PAH not responding adequately to their current therapy. Treatment with riociguat was associated with a mean improvement in 6MWD of 31 m over 24 weeks, a mean change of –347 pg/mL in NT-proBNP and improved WHO FC in 54% of patients who switched to riociguat from a PDE-5i. Although patients with CTD were excluded from the study, results from phase 3 trials have already demonstrated efficacy in this patient population. In these three cases, substitution with riociguat was associated with clinical and hemodynamic improvements similar
to those seen in the PATENT-1 and PATENT-2 PAH-CTD and PAH-SSc subpopulations, although improvement in these subpopulations was less pronounced than in patients with IPAH. Previous studies in patients with PAH-CTD and PAH-SSc have also demonstrated decreased response to therapy in this patient population.\textsuperscript{15,16} In PATENT-1 and -2, patients with PAH-SSc randomized to placebo experienced significant deterioration in 6MWD—more so than the PAH-CTD population—whereas those receiving riociguat saw sustained improvement at the two-year cutoff.\textsuperscript{13} Stabilization of 6MWD may be indicative of response to therapy in specific PAH subpopulations given the underlying pathophysiology of CTD and the effect of musculoskeletal involvement on exercise capacity and overall mobility.\textsuperscript{15,20} The REVEAL registry identified unique baseline risk factors associated with mortality in the SSc population, among them male sex, age > 60 years, systolic blood pressure < 110 mmHg, 6MWD < 165 m, mean right atrial pressure > 20 mmHg within one year, and PVR > 2560 dyn s cm\textsuperscript{-5}.\textsuperscript{15,20}

Also of potential interest to this patient population, sGC stimulation has been shown to inhibit transforming growth factor (TGF)-β–induced collagen release and fibroblast-to-myofibroblast differentiation in dermal fibroblasts from SSc patients and healthy volunteers.\textsuperscript{21,22} sGC stimulation also inhibited dermal fibrosis in mouse models of SSc (bleomycin-induced dermal fibrosis, an inflammation-dependent model; Tsk-1 mice, an inflammation-independent model; and mice expressing constitutively active TGF-β receptor I) as assessed by skin thickening, hydroxyproline content, and myofibroblast counts.\textsuperscript{21,22} Thus, the effect of riociguat in these patients, compared with a PDE-5i, might be due to its differential mechanism of augmenting the effect of NO and/or, to some degree, by the antifibrotic effect observed in preclinical models of SSc. This aspect of sGC stimulation is currently under further investigation in the ongoing RISE-SSc trial (NCT02283762).

In sum, these three cases demonstrate that in patients with PAH-CTD who have an inadequate response to a PDE-5i, switching to riociguat has the potential to improve clinical and hemodynamic parameters and showed a favorable tolerability profile in clinical trials and in our select patients.

Conflict of interest

AR reports personal fees from Bayer, United Therapeutics, and Actelion. RB reports speaker fees from Actelion and United Therapeutics. HF reports grants and personal fees from Actelion, Gilead, and United Therapeutics/Lung and personal fees from Bayer and Bellerophon.

Funding

Article processing charges for this article were funded by Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA. Medical writing and editing assistance were provided by Adelphi Communications, LLC, and were funded by Bayer Healthcare.

References

1. McLaughlin VV, Presberg KW, Doyle RL, et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126: 78S–92S.
2. Galié N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 2013; 62(25 Suppl): D60–D72.
3. Galié N, Humbert M, Vachiery J-L, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2015; 46: 903–975.
4. Galié N, Barberà AE, Frost H-A, et al. Initial use of ambisentan plus tadalafil in pulmonary arterial hypertension. New Engl J Med 2015; 373: 834–844.
5. Ghofrani HA, D’Armini AM, Grimminger F, et al.; CHEST-1 Study Group. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 2013; 369(4): 319–329.
6. Ghofrani HA, Galié N, Grimminger F, et al.; PATENT-1 Study Group. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013; 369(4): 330–340.
7. Stasch JP, Pacher P and Evgenov OV. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation 2011; 123: 2263–2273.
8. Stasch JP and Evgenov OV. Soluble guanylate cyclase stimulators in pulmonary hypertension. Handb Exp Pharmacol 2013; 218: 279–313.
9. Kaneko FT, Arroliga AC, Dweik RA, et al. Biochemical reaction products of nitric oxide as quantitative markers of primary pulmonary hypertension. Am J Respir Crit Care Med 1998; 158: 917–923.
10. Schermuly RT, Ghofrani HA, Wilkins MR, et al. Mechanisms of disease: pulmonary arterial hypertension. Nat Rev Cardiol 2011; 8: 443–445.
11. Mittendorf J, Weigand S, Alonso-Alia C, et al. Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. Chem Med Chem 2009; 4: 853–865.
12. Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62: D34–D41.
13. Humbert M, Coghlan, Ghofrani H-A, et al. Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. Ann Rheum Dis 2017; 76: 422–426.
14. Hoepf MM, Corris PA, Klinger JR, et al. RESPITE: Riociguat in pulmonary arterial hypertension patients with an inadequate response to phosphodiesterase type 5 inhibitors. Eur Respir J 2016; 48: OA263.
15. Mathai SC and Hassoun PM. Pulmonary arterial hypertension in connective tissue diseases. Heart Fail Clin 2012; 8: 413–425.
16. Rhee RL, Gabler NB, Sangani S, et al. Comparison of treatment response in idiopathic and connective tissue disease-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2015; 192: 1111–1117.
17. van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis. An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis Rheum 2013; 65: 2373–2347.
18. McGoon M, Guttermann D, Steen, et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension:
ACCP evidence-based clinical practice guidelines. Chest 2004; 126: 14S–34S.

19. Frost AE, Barst RJ, Hoeper MM, et al. Long-term safety and efficacy of imatinib in pulmonary arterial hypertension. J Heart Lung Transplant 2015; 34: 1366–1375.

20. Chung L, Farber HW, Benza R, et al. Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry. CHEST 2014; 146(6): 1494–1504.

21. Beyer C, Reich N, Schindler SC, et al. Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis. Ann Rheum Dis 2012; 71(6): 1019–1026.

22. Beyer C, Zenzmaier C, Palumbo-Zerr K, et al. Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGFβ signaling. Ann Rheum Dis 2015; 74(7): 1408–1416.